Atlas Trials

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

Clinical trial NCT05953584 · RECRUITING

Trial details

NCT number
NCT05953584
Sponsor
Forma Therapeutics, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Sickle Cell Disease
Start date
2023-06-20
Primary completion
2027-09-20
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.